Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough
|
Jun 2023
|
American Journal of Hematology
|
myelodysplastic syndromes (MDS)
|
IPSS-M in myelodysplastic neoplasms arising from aplastic anemia and paroxysmal nocturnal hemoglobinuria
|
Jun 2023
|
Blood
|
aplastic anemia
|
Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia
|
Jun 2023
|
Blood
|
aplastic anemia
|
Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria
|
Jun 2023
|
Blood Advances
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes?
|
Jun 2023
|
Lancet
|
myelodysplastic syndromes (MDS)
|
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)
|
Jun 2023
|
Journal of Clinical Oncology
|
myelodysplastic syndromes (MDS)
|
TERC haploid cell reprogramming: a novel therapeutic strategy for aplastic anemia
|
Jun 2023
|
Molecular Medicine
|
aplastic anemia
|
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial
|
Jun 2023
|
Lancet
|
myelodysplastic syndromes (MDS)
|
Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management
|
Jun 2023
|
American Journal of Hematology
|
myelodysplastic syndromes (MDS)
|
Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real-world retrospective study
|
Jun 2023
|
European Journal of Haematology
|
aplastic anemia
|